A long-term trial with thalidomide indicates it may be a promising compound for use in patients with treatment-resistant ankylosing spondylitis.
In a joint Chinese-American study, researchers had two aims: to find if thalidomide could be efficacious in the treatment of ankylosing spondylitis and whether it would produce changes in expression of genes in peripheral blood mononuclear cells (PBMC).
The open label study was led by Dr David Tak Yan Yu, Rheumatology Division, University o of California, Los Angeles, United States, and colleagues in China. Thirty men who had treatment-refractory ankylosing spondylitis were recruited into the 12-month open study. Thalidomide was given at a dosage of 200 mg/day.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!